<prof_article_slide_presentation><front_label>Front Matter</front_label><above_title/><title/><contrbtr_pre_content><p>WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.</p></contrbtr_pre_content><contrbtr_byline><p>(Names and degrees only, separated by semicolons)Henri-Jean Aubin, MD, PhD; Peter Hajek, PhD; Serena Tonstad, MD, PhDLocation/map info:(City, State – Venue, Room)Ludwig-Maximilians-University, Psychiatric Clinic, Munich, GermanyDate &amp; Time:September 7, 2018 at 12:30 to 13:30Speakers/Program Info/Faculty information/Disclosures*Disclosures are not to be used for the registration page*Speakers&lt;em&gt;Names, title, affiliations &lt;/em&gt;&lt;em&gt;Disclosures &lt;/em&gt;(Disclosures not to be used for the registration page, only for the certificate and enduring page)eg:ModeratorAldo P. Maggioni, MDDirector Research Center of Italian Association of Hospital Cardiologists (ANMCO) Firenze, ItalyDisclosure: Aldo P. Maggioni, MD, has disclosed the following relevant financial relationships:Served as an advisor or consultant for:...PanelistsClyde W. Yancy, MD, MScMagerstadt Professor of MedicineChiefDivision of Cardiology Northwestern University Feinberg School of MedicineChicago, Illinois, United StatesDisclosure: Clyde W. Yancy, MD, MSc, has disclosed the following relevant financial relationships:Served as an advisor or consultant for:...Henri-Jean Aubin, MD, PhDProfessorUniversity Paris-SudDirector of the Addiction Science Research Group in the INSERM 1018 UnitVillejuif, FranceDisclosure: Henri-Jean Aubin, MD, PhD, has disclosed the following relevant financial relationships: ☒ Served as an advisor or consultant for: D&amp;A Pharma; Ethypharm; Lundbeck, Inc.; Pfizer Inc. ☒ Served as a speaker or a member of a speakers bureau for: Lundbeck, Inc.; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Pierre Fabre Sante; Pfizer Inc. Peter Hajek, PhDProfessor of Clinical PsychologyQueen Mary University of LondonLondon, United KingdomDisclosure: Peter Hajek, PhD, has disclosed the following relevant financial relationships: ☒ Served as an advisor or consultant for: Pfizer Inc. Philip Toennesen, MD, DMScSenior Consultant, Specialist in Pulmonary MedicineExpert in Sleep Disorders and Smoking CessationDepartment of Sleep DisordersRigshospitaletCopenhagen, DenmarkDisclosure: Philip Toennesen, MD, has disclosed the following relevant financial relationships: ☒ Served as an advisor or consultant for: Fertim Pharma; Pfizer Inc.☒ Served as a speaker or a member of a speakers bureau for: Fertim Pharma; Pfizer Inc. Serena Tonstad, MD, PhDProfessorLoma Linda UniversityLoma Linda, California, United States Head PhysicianOslo University HospitalOslo, NorwayDisclosure: Serena Tonstad, MD, PhD, has disclosed the following relevant financial relationships: ☒ Served as an advisor or consultant for: Pfizer Inc. ☒ Served as a speaker or a member of a speakers bureau for: Pfizer Inc. Program Details***A start and end time for the overall event are required - specific start times for each section are optional, if available. Please use 24-hour clock for international programs***e.g.:October 31, 2017  5:30 AMBreakfast &amp; Registration6:00 AMPresentation6:30 AMWelcome and IntroductionsMarin H. Kollef, MD7:00 AMRespiratory Failure and Ventilator-Associated Pneumonia: A Critical Problem For Critical CareAndrew F. Shorr, MD7:30 AMTreating Gram-Negative Pneumonia Today: Challenges and ConsiderationsLee E. Morrow, MD8:00 AMTreating Gram-Negative Pneumonia Tomorrow: Inhaled AntibioticsMarin H. Kollef, MD8:30 AMAntimicrobial StewardshipRichard G. Wunderink, MD9:00 AMClosing RemarksMarin H. Kollef, MD9:30 AMQuestion &amp; AnswerSeptember 7, 201812:30Welcome and IntroductionsHenri-Jean Aubin, MD, PhD12:33The Importance of a Complete QuitHenri-Jean Aubin, MD, PhD12:43Pharmacologic Therapies for Smoking Cessation: The EvidenceSerena Tonstad, MD, PhD12:53E-Cigarettes and "Heat-Not-Burn" Devices: Is There a Role?Peter Hajek, PhD13:03What Do the Guidelines Say?Philip Toennesen, MD, DMSc13:13Panel Debate, Discussion, and Audience Q&amp;AAll Faculty13:28Wrap-Up and Closing Remarks Activity InformationLeft-side Content</p></contrbtr_byline><contrbtr_bulk_info/><contrbtr_post_content/><supprtr_grant_group/><body_label>Body</body_label><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header/><subsec_element><subsec_header/><slide_intro/><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide1.png</sec_img><sec_label>Slide 1.</sec_label><sec_caption/><sec_txt><h3> The Big Debate: Pharmacologic vs Alternative Approaches in Smoking Cessation</h3></sec_txt><sec_alt_txt>Slide 1.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide2.png</sec_img><sec_label>Slide 2.</sec_label><sec_caption/><sec_txt><h3> Program Agenda</h3></sec_txt><sec_alt_txt>Slide 2.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide3.png</sec_img><sec_label>Slide 3.</sec_label><sec_caption/><sec_txt><h3> The Importance of a Complete Quit</h3></sec_txt><sec_alt_txt>Slide 3.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide4.png</sec_img><sec_label>Slide 4.</sec_label><sec_caption/><sec_txt><h3> Worldwide Leading Causes of Attributable Global Mortality<sup type="ref">[1]</sup></h3></sec_txt><sec_alt_txt>Slide 4.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide5.png</sec_img><sec_label>Slide 5.</sec_label><sec_caption/><sec_txt><h3> Smoking Leads to an 11-Year Loss of Life Span<sup type="ref">[2]</sup></h3></sec_txt><sec_alt_txt>Slide 5.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide6.png</sec_img><sec_label>Slide 6.</sec_label><sec_caption/><sec_txt><h3> Mortality and Morbidity Rates Associated With Smoking<sup type="ref">[2,3]</sup></h3><ul><li>	The figure on the left shows that there is a monotonous dose effect relationship between cigarettes per day and all-cause mortality
<ul><li>	This means that even low smoking rates are associated with an increased risk of mortality </li></ul></li><li>	In the specific case of cardiovascular disease, most of the mortality risk is borne by low smoking rates, as seen in the curve on the right </li></ul></sec_txt><sec_alt_txt>Slide 6.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide7.png</sec_img><sec_label>Slide 7.</sec_label><sec_caption/><sec_txt><h3> Mortality and Morbidity Rates Associated With Smoking (cont)<sup type="ref">[2,4]</sup></h3></sec_txt><sec_alt_txt>Slide 7.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide8.png</sec_img><sec_label>Slide 8.</sec_label><sec_caption/><sec_txt><h3> All-Cause Mortality Risk Reduction After Quitting Smoking<sup type="ref">[5]</sup></h3><ul><li>	It is believed that complete quit is the safest and most effective way to reduce the all-cause mortality associated with smoking</li><li>	It is also believed that the reduction of all-cause mortality stabilizes roughly 10 to 15 years after complete smoking cessation</li></ul></sec_txt><sec_alt_txt>Slide 8.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide9.png</sec_img><sec_label>Slide 9.</sec_label><sec_caption/><sec_txt><h3> Little Evidence of All-Cause Mortality Risk Reduction After Smoking Reduction<sup type="ref">[6-9]</sup></h3><ul><li>	It is important to keep in mind that in all the studies shown on this slide, smoking reduction was not supported by any nicotine replacement use </li><li>	Moreover, it is known that reduction of cigarettes per day does not reflect reduction of toxin exposure</li></ul></sec_txt><sec_alt_txt>Slide 9.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide10.png</sec_img><sec_label>Slide 10.</sec_label><sec_caption/><sec_txt><h3> Harm Reduction Concept: People Who Do Not Want to Give Up Tobacco or Nicotine Use Completely<sup type="ref">[10]</sup></h3></sec_txt><sec_alt_txt>Slide 10.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide11.png</sec_img><sec_label>Slide 11.</sec_label><sec_caption/><sec_txt><h3>Cigarette Smoking Causes the Most Harm<sup type="ref">[11]</sup></h3></sec_txt><sec_alt_txt>Slide 11.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide12.png</sec_img><sec_label>Slide 12.</sec_label><sec_caption/><sec_txt><h3> Conclusions</h3></sec_txt><sec_alt_txt>Slide 12.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide13.png</sec_img><sec_label>Slide 13.</sec_label><sec_caption/><sec_txt><h3> Pharmacologic Therapies for Smoking Cessation: The Evidence</h3></sec_txt><sec_alt_txt>Slide 13.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide14.png</sec_img><sec_label>Slide 14.</sec_label><sec_caption/><sec_txt><h3> Nicotine Replacement Therapy vs Control for Smoking Cessation<sup type="ref">[12]</sup></h3><ul><li>	Nicotine replacement therapy is the oldest, most established, and most used therapy for smoking cessation</li><li>	Based on the results of this analysis, the Cochrane Group collaborators stated that they will never do another meta-analysis of this type, because the evidence is so strong for nicotine replacement against placebo
<ul><li>	Subgroup and other types of analyses may be conducted, for example, comparing nicotine replacement with e-cigarettes or other comparators, but the placebo comparison is firmly established at this time</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 14.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide15.png</sec_img><sec_label>Slide 15.</sec_label><sec_caption/><sec_txt><h3> First-Line Drugs in Smoking Cessation: Meta-Analysis of Cochrane Register Efficacy Data<sup type="ref">[12-15]</sup></h3></sec_txt><sec_alt_txt>Slide 15.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide16.png</sec_img><sec_label>Slide 16.</sec_label><sec_caption/><sec_txt><h3> Efficacy of Varenicline: Phase 3 and 4 Studies (Weeks 9-12)<sup type="ref">[16-25]</sup></h3></sec_txt><sec_alt_txt>Slide 16.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide17.png</sec_img><sec_label>Slide 17.</sec_label><sec_caption/><sec_txt><h3> Efficacy of Varenicline: Phase 3 and 4 Studies (Weeks 9-52)<sup type="ref">[16,17,21-23,25]</sup></h3></sec_txt><sec_alt_txt>Slide 17.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide18.png</sec_img><sec_label>Slide 18.</sec_label><sec_caption/><sec_txt><h3> Quit Rates Flexible Quit Date Study<sup type="ref">[24]</sup></h3></sec_txt><sec_alt_txt>Slide 18.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide19.png</sec_img><sec_label>Slide 19.</sec_label><sec_caption/><sec_txt><h3> Varenicline Maintenance Study<sup type="ref">[26]</sup></h3></sec_txt><sec_alt_txt>Slide 19.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide20.png</sec_img><sec_label>Slide 20.</sec_label><sec_caption/><sec_txt><h3> Maintenance Treatment With Varenicline in Patients With Schizophrenia and Bipolar Disorder<sup type="ref">[27]</sup></h3></sec_txt><sec_alt_txt>Slide 20.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide21.png</sec_img><sec_label>Slide 21.</sec_label><sec_caption/><sec_txt><h3> EAGLES: Continuous Abstinence Rates in Psychiatric and Nonpsychiatric Cohorts<sup type="ref">[28]</sup></h3><ul><li>	This is the EAGLES study and included over 8000 subjects, both people with psychiatric disease and people without known psychiatric disease</li><li>	The study was sponsored by both producers of varenicline and of bupropion and in collaboration with health authorities</li></ul></sec_txt><sec_alt_txt>Slide 21.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide22.png</sec_img><sec_label>Slide 22.</sec_label><sec_caption/><sec_txt><h3> Primary Endpoint for the EAGLES Study: Nonpsychiatric Adverse Events<sup type="ref">[28]</sup></h3></sec_txt><sec_alt_txt>Slide 22.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide23.png</sec_img><sec_label>Slide 23.</sec_label><sec_caption/><sec_txt><h3> Tolerability and Safety Issues<sup type="ref">[29]</sup></h3></sec_txt><sec_alt_txt>Slide 23.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide24.png</sec_img><sec_label>Slide 24.</sec_label><sec_caption/><sec_txt><h3> Physician Perspectives<sup type="ref">[30]</sup></h3></sec_txt><sec_alt_txt>Slide 24.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide25.png</sec_img><sec_label>Slide 25.</sec_label><sec_caption/><sec_txt><h3>Lack of Readiness to Use Pharmacologic Options (Smoker)</h3></sec_txt><sec_alt_txt>Slide 25.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide26.png</sec_img><sec_label>Slide 26.</sec_label><sec_caption/><sec_txt><h3> E-Cigarettes and "Heat-Not-Burn" Devices: Is There a Role?</h3></sec_txt><sec_alt_txt>Slide 26.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide27.png</sec_img><sec_label>Slide 27.</sec_label><sec_caption/><sec_txt><h3> Current Controversy</h3><ul><li>	In my opinion, what we see in our field is this split in the attitude to e-cigarettes, which I believe is based on priority</li><li>	If the priority is smoke-related death and disease, then there is a sort of pragmatic perspective in which alternative lower-risk nicotine devices may appear as promising to lower the total of death and disease from smoking</li><li>	By contrast, the other view is the concern that providing nicotine in the less dangerous form still maintains and may even increase nicotine use in the population
<ul><li>	Hence, safe nicotine devices are both a problem and a risk</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 27.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide28.png</sec_img><sec_label>Slide 28.</sec_label><sec_caption/><sec_txt><h3> Recent UK Reports Regarding the Use of E-Cigarettes<sup type="ref">[31-33]</sup></h3></sec_txt><sec_alt_txt>Slide 28.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide29.png</sec_img><sec_label>Slide 29.</sec_label><sec_caption/><sec_txt><h3> Conclusions of UK Reviews</h3></sec_txt><sec_alt_txt>Slide 29.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide30.png</sec_img><sec_label>Slide 30.</sec_label><sec_caption/><sec_txt><h3> The Opposite View</h3></sec_txt><sec_alt_txt>Slide 30.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide31.png</sec_img><sec_label>Slide 31.</sec_label><sec_caption/><sec_txt><h3> Time Will Tell</h3></sec_txt><sec_alt_txt>Slide 31.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide32.png</sec_img><sec_label>Slide 32.</sec_label><sec_caption/><sec_txt><h3> UK Experience So Far</h3></sec_txt><sec_alt_txt>Slide 32.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide33.png</sec_img><sec_label>Slide 33.</sec_label><sec_caption/><sec_txt><h3> "Heat-Not-Burn" Products<sup type="ref">[34]</sup></h3></sec_txt><sec_alt_txt>Slide 33.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide34.png</sec_img><sec_label>Slide 34.</sec_label><sec_caption/><sec_txt><h3> Cigarette Sales Decline: Japan, 2014-2018</h3></sec_txt><sec_alt_txt>Slide 34.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide35.png</sec_img><sec_label>Slide 35.</sec_label><sec_caption/><sec_txt><h3>The DUO Study<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 35.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide36.png</sec_img><sec_label>Slide 36.</sec_label><sec_caption/><sec_txt><h3> Background<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 36.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide37.png</sec_img><sec_label>Slide 37.</sec_label><sec_caption/><sec_txt><h3> DUO Study<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 37.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide38.png</sec_img><sec_label>Slide 38.</sec_label><sec_caption/><sec_txt><h3> Study Procedures<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 38.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide39.png</sec_img><sec_label>Slide 39.</sec_label><sec_caption/><sec_txt><h3> Are Dual Users Interested in Varenicline?<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 39.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide40.png</sec_img><sec_label>Slide 40.</sec_label><sec_caption/><sec_txt><h3> Did Those Wanting and Not Wanting Varenicline Differ?<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 40.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide41.png</sec_img><sec_label>Slide 41.</sec_label><sec_caption/><sec_txt><h3> Quitting Outcomes<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 41.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide42.png</sec_img><sec_label>Slide 42.</sec_label><sec_caption/><sec_txt><h3> Quitting Vaping, Smoking, and Both<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 42.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide43.png</sec_img><sec_label>Slide 43.</sec_label><sec_caption/><sec_txt><h3> Changes in Enjoyment of Smoking and Vaping<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 43.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide44.png</sec_img><sec_label>Slide 44.</sec_label><sec_caption/><sec_txt><h3> Conclusions<sup type="ref">[35]</sup></h3></sec_txt><sec_alt_txt>Slide 44.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide45.png</sec_img><sec_label>Slide 45.</sec_label><sec_caption/><sec_txt><h3> What Do the Guidelines Say?</h3></sec_txt><sec_alt_txt>Slide 45.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide46.png</sec_img><sec_label>Slide 46.</sec_label><sec_caption/><sec_txt><h3> WHO Framework Convention on Tobacco Control<sup type="ref">[36]</sup></h3></sec_txt><sec_alt_txt>Slide 46.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide47.png</sec_img><sec_label>Slide 47.</sec_label><sec_caption/><sec_txt><h3> WHO Urges Restrictions on E-Cigarettes (2016)<sup type="ref">[37]</sup></h3></sec_txt><sec_alt_txt>Slide 47.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide48.png</sec_img><sec_label>Slide 48.</sec_label><sec_caption/><sec_txt><h3> Interventions to Reduce Harm From Continued Tobacco Use<sup type="ref">[10]</sup></h3></sec_txt><sec_alt_txt>Slide 48.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide49.png</sec_img><sec_label>Slide 49.</sec_label><sec_caption/><sec_txt><h3> NICE 2018: 1.5 Advice on E-Cigarettes for Health and Social Care Workers in Primary and Community Settings<sup type="ref">[38]</sup></h3></sec_txt><sec_alt_txt>Slide 49.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide50.png</sec_img><sec_label>Slide 50.</sec_label><sec_caption/><sec_txt><h3> Clinical Guidelines for General Practice<sup type="ref">[39]</sup></h3></sec_txt><sec_alt_txt>Slide 50.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide51.png</sec_img><sec_label>Slide 51.</sec_label><sec_caption/><sec_txt><h3> Clinical Guidelines for General Practice (cont)<sup type="ref">[39]</sup></h3></sec_txt><sec_alt_txt>Slide 51.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide52.png</sec_img><sec_label>Slide 52.</sec_label><sec_caption/><sec_txt><h3> Clinical Guidelines for General Practice (cont)<sup type="ref">[39]</sup></h3></sec_txt><sec_alt_txt>Slide 52.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide53.png</sec_img><sec_label>Slide 53.</sec_label><sec_caption/><sec_txt><h3> Canadian Smoking Cessation Guideline Summary Statement<sup type="ref">[40]</sup></h3></sec_txt><sec_alt_txt>Slide 53.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide54.png</sec_img><sec_label>Slide 54.</sec_label><sec_caption/><sec_txt><h3> Canadian Smoking Cessation Guideline Summary Statement (cont)<sup type="ref">[40]</sup></h3></sec_txt><sec_alt_txt>Slide 54.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide55.png</sec_img><sec_label>Slide 55.</sec_label><sec_caption/><sec_txt><h3> Canadian Smoking Cessation Guideline Summary Statement (cont)<sup type="ref">[40]</sup></h3></sec_txt><sec_alt_txt>Slide 55.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide56.png</sec_img><sec_label>Slide 56.</sec_label><sec_caption/><sec_txt><h3> Medical Societies</h3></sec_txt><sec_alt_txt>Slide 56.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide57.png</sec_img><sec_label>Slide 57.</sec_label><sec_caption/><sec_txt><h3> AHA Smoking Guidelines 2014</h3></sec_txt><sec_alt_txt>Slide 57.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide58.png</sec_img><sec_label>Slide 58.</sec_label><sec_caption/><sec_txt><h3> Position Statement of the Forum of International Respiratory Societies: E-Cigarettes<sup type="ref">[41]</sup></h3></sec_txt><sec_alt_txt>Slide 58.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide59.png</sec_img><sec_label>Slide 59.</sec_label><sec_caption/><sec_txt><h3> Conclusions</h3></sec_txt><sec_alt_txt>Slide 59.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/903/975/Slide60.png</sec_img><sec_label>Slide 60.</sec_label><sec_caption/><sec_txt><h3> Thank You</h3></sec_txt><sec_alt_txt>Slide 60.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img/><sec_label/><sec_caption/><sec_txt><em>This content has been condensed for improved clarity.</em></sec_txt><sec_alt_txt/><qna_form/></slide_grp></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label><p>Abbreviations</p></toc_label><toc_type>Sidebar</toc_type><sec_element><sec_header><p>Abbreviations</p></sec_header><subsec_element><subsec_header/><slide_intro/></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>References</toc_type><sec_element><sec_header/><subsec_element><subsec_header/><slide_intro/></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label><p>Audience Q &amp; A</p></toc_label><toc_type>Sidebar</toc_type><sec_element><sec_header><p>Audience Q &amp; A</p></sec_header><subsec_element><subsec_header/><slide_intro><div class="app-loading"><div class="webcomp-player" data-config="en/pi/editorial/studio/configs/2019/education/903975/903975_3.json" data-playertype="edu" id="cme-video-player">
                &#160;
            </div></div></slide_intro></subsec_element></sec_element><pg_footnotes/></toc_element><back_label>Back Matter</back_label><ref_grp><ref_item/></ref_grp><cpyrt_holder><p>WebMD Global, LLC</p></cpyrt_holder><cpyrt_ovrd/><disclmr_ovrd/><bkmtr_front><p><strong>Disclaimer</strong></p><p>The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.</p></bkmtr_front><bkmtr_glossary/><bkmtr_ack/><bkmtr_discl/><bkmtr_funding/><bkmtr_reprnt_addr/><bkmtr_abbr_notes/><bkmtr_last/><img_ttl_bkgrd/><img_publ_logo/></prof_article_slide_presentation>